Omodysplasia 2 (OMOD2) Cell Models for Research

Omodysplasia 2 (OMOD2) is an ultra-rare autosomal recessive skeletal dysplasia characterized by severe shortening of the limbs (rhizomelic dwarfism), facial dysmorphism, and variable intellectual disability. The exact prevalence is unknown, but it is estimated to affect fewer than 1 in 1,000,000 individuals worldwide. Due to its rarity, there are no large-scale epidemiological studies; however, case reports and small series have been published. The condition is caused by mutations in the GPC6 gene, which encodes glypican 6, a heparan sulfate proteoglycan involved in Wnt signaling and bone development. The clinical impact is significant, with affected individuals requiring orthopedic interventions and lifelong management. Research on OMOD2 is crucial for understanding skeletal development and for developing potential therapies.

OMOD2 serves as an excellent model for studying the molecular mechanisms of skeletal development and the role of heparan sulfate proteoglycans in signaling pathways. The disease is monogenic, making it amenable to gene editing to create precise cellular models. Public datasets, such as those in ClinVar and UniProt, provide information on pathogenic variants. Open questions include the exact role of GPC6 in chondrocyte differentiation and the potential for targeted therapies. Gene-edited cell lines with GPC6 knockouts or patient-specific mutations can be used to dissect these mechanisms and screen for therapeutic compounds.

The primary pathway affected in OMOD2 is the Wnt signaling pathway, which is critical for bone development. GPC6 is a glypican that modulates Wnt ligand binding and receptor activation. Loss of GPC6 function leads to disrupted Wnt signaling, affecting chondrocyte proliferation and differentiation. Additionally, GPC6 interacts with other signaling molecules, including fibroblast growth factors (FGFs) and bone morphogenetic proteins (BMPs), which are also involved in skeletal development. The disruption of these pathways results in the characteristic limb shortening and other skeletal abnormalities.

• • Wnt/β-catenin signaling: GPC6 loss reduces Wnt signaling, leading to decreased chondrocyte proliferation.
• • FGF signaling: GPC6 modulates FGF ligand availability, affecting growth plate development.
• • BMP signaling: GPC6 may influence BMP receptor binding, altering osteoblast differentiation.
• • Hedgehog signaling: Potential cross-talk with GPC6, though less characterized.

Organoids derived from induced pluripotent stem cells (iPSCs) carrying GPC6 mutations can recapitulate skeletal development and are valuable for studying disease mechanisms.

• • Gpc6 knockout mouse: Shows skeletal abnormalities similar to OMOD2, including limb shortening.
• • Patient-derived xenografts (PDX): Not commonly used for OMOD2 due to rarity, but possible with patient-derived chondrocytes.
• • Genetically engineered mouse models (GEMM): Conditional knockouts can be used to study tissue-specific effects.
• • Induced models: CRISPR-mediated knockout in mice to model the disease.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise GPC6 mutations. For example, a GPC6 knockout cell line can be generated in HEK293 or U2OS cells to study loss-of-function effects. Alternatively, knock-in of a specific patient mutation (e.g., p.Arg371Ter) can be introduced to model the disease more accurately. These gene-edited cell lines are commercially available from various sources, ensuring sequence verification and quality. They are essential for functional studies, drug screening, and target validation.

Gene-edited cell lines with GPC6 knockout or patient-specific mutations are used to validate the role of GPC6 in skeletal development. For example, knockout of GPC6 in chondrogenic cell lines can be used to assess changes in gene expression and signaling pathway activity. This helps identify downstream targets and potential therapeutic interventions.

Isogenic cell line pairs (wild-type vs. GPC6 knockout) are ideal for high-throughput screening of compounds that may rescue the phenotype. For instance, small molecules that activate Wnt signaling could be tested for their ability to restore chondrocyte proliferation. Additionally, these models can be used to study resistance mechanisms to drugs that target skeletal pathways.

CRISPR-based synthetic lethality screens using GPC6 knockout cells can identify genes that, when silenced, are lethal only in the absence of GPC6. This can reveal potential drug targets for OMOD2 and related skeletal disorders. Furthermore, gene-edited cells can be used to identify biomarkers for disease progression or response to therapy.